QUEST DIAGNOSTICS INC News
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
see moreQUEST DIAGNOSTICS INC Market News
7d
Quest Diagnostics' Q2 2026 Earnings Surpass Expectations; Full-Year Guidance Raised
- Quest Diagnostics reports strong Q2 2026 earnings, raises full-year guidance.
9d
Quest Diagnostics Reports Strong Q2 2026 Results, Raises Full-Year Guidance
Quest Diagnostics posts robust Q2 2026 earnings, boosts annual outlook.
16d
Quest Diagnostics Integrates Oncology Tests into OncoEMR, Enhancing Cancer Care
Quest Diagnostics integrates Haystack MRD test into OncoEMR for better cancer care.
23d
Quest Diagnostics' Haystack MRD Test Gains New York Approval, Enhancing Cancer Detection
Quest Diagnostics' Haystack MRD test approved in New York, expanding cancer detection.
29d
Quest Diagnostics' Recent Developments and Financial Performance
An overview of Quest Diagnostics' recent financial results and strategic initiatives.
25 May at 04:30
Quest DGX Names Strategy Chief; M&A Focused Update
Quest Diagnostics appointed Benjamin Beauvalot as Chief Strategy & M&A Officer, signaling renewed acquisition focus. Coupled with peer Labcorp's raised guidance and shifting specialty diagnostics activity, the move reshapes near-term expectations for DGX around dealmaking, margin management, and competitive positioning.
18 May at 04:30
Quest Diagnostics Rally: Q1 Beat Lifts PTs to $245
Quest Diagnostics (DGX) delivered a strong Q1 2026 quarter with revenue and EPS beats and raised guidance, prompting multiple analyst price-target increases and fresh institutional buying. Concrete earnings and capital-markets moves are reshaping near-term sentiment for the stock.